An acellular pertussis vaccine composed of genetically detoxified pertussis toxin (PT-9K/129G), filamentous haemagglutinin (FHA) and pertactin (69 kDa protein) was evaluated in adult volunteers, in double blind, versus placebo. No fever was reported in either group. Mild local reactions were reported after injection of both vaccine and placebo. After the first dose a marked increase in antibodies to PT, FHA and 69 kDa protein was seen in vaccinated subjects with the exception of one who responded well to PT and FHA but did not show a humoral response to the 69 kDa protein. All vaccinees acquired cellular immunity against the three antigens. No significant variation was observed in the humoral or cellular responses after the second dose.

Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 K / Podda, A.; Nencioni, L.; Marsili, I.; Peppoloni, Samuele; Volpini, G.; Donati, D.; DI TOMMASO, A.; Magistris, M. T. AND RAPPUOLI R.. - In: VACCINE. - ISSN 0264-410X. - STAMPA. - 9:(1991), pp. 741-745.

Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 K

PEPPOLONI, Samuele;
1991

Abstract

An acellular pertussis vaccine composed of genetically detoxified pertussis toxin (PT-9K/129G), filamentous haemagglutinin (FHA) and pertactin (69 kDa protein) was evaluated in adult volunteers, in double blind, versus placebo. No fever was reported in either group. Mild local reactions were reported after injection of both vaccine and placebo. After the first dose a marked increase in antibodies to PT, FHA and 69 kDa protein was seen in vaccinated subjects with the exception of one who responded well to PT and FHA but did not show a humoral response to the 69 kDa protein. All vaccinees acquired cellular immunity against the three antigens. No significant variation was observed in the humoral or cellular responses after the second dose.
9
741
745
Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 K / Podda, A.; Nencioni, L.; Marsili, I.; Peppoloni, Samuele; Volpini, G.; Donati, D.; DI TOMMASO, A.; Magistris, M. T. AND RAPPUOLI R.. - In: VACCINE. - ISSN 0264-410X. - STAMPA. - 9:(1991), pp. 741-745.
Podda, A.; Nencioni, L.; Marsili, I.; Peppoloni, Samuele; Volpini, G.; Donati, D.; DI TOMMASO, A.; Magistris, M. T. AND RAPPUOLI R.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/457066
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 39
social impact